Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines

Vladimir Shnaydman
doi: https://doi.org/10.1101/2020.11.01.20214122
Vladimir Shnaydman
ORBee Consulting
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vladimir.shnaydman@orbeeconsulting.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Executive summary

The paper presents the methodology and modeling results for COVID-19 vaccines portfolio forecasting, including R&D output (rate and likelihood of approvals at a vaccine technology platform level) and manufacturing production output to meet worldwide demand.

In order to minimize the time and risk of global vaccination, scaling up of Operation Warp Speed (OWS) and other programs could be very beneficial, leading to increased financing for additional vaccine development programs, in both Phase III clinical trials and in manufacturing. It would also lead to a reduction of the global production time for world vaccination, from 75 months for a baseline scenario to 36 months, reducing potential global GDP loss by as much as US$4.2 trillion (US ∼ $1 trillion) when compared to the baseline scenario.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • “Could you, please, share your forecasts?” “Yes. I can give optimistic, realistic and pessimistic ones.” “Great! How about realistic forecast?” “It is two times worse that the pessimistic one.”

  • 2 Input data presented in the Appendix – Model_data_102020.xls

Data Availability

Data is available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 04, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines
Vladimir Shnaydman
medRxiv 2020.11.01.20214122; doi: https://doi.org/10.1101/2020.11.01.20214122
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines
Vladimir Shnaydman
medRxiv 2020.11.01.20214122; doi: https://doi.org/10.1101/2020.11.01.20214122

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5212)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (748)
  • Geriatric Medicine (76)
  • Health Economics (212)
  • Health Informatics (692)
  • Health Policy (351)
  • Health Systems and Quality Improvement (222)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5813)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (757)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (853)
  • Public and Global Health (1992)
  • Radiology and Imaging (343)
  • Rehabilitation Medicine and Physical Therapy (155)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)